10x_Science Seed Raise

Protein characterization is the lab step where scientists check whether a drug protein is the molecule they think they made. On April 22, 10x Science said it raised a $4.8 million seed round to automate that work with artificial intelligence. (prnewswire.com) The San Francisco startup said Initialized Capital led the round, with Y Combinator, Civilization Ventures, Founder Factor, and angel investors also participating. TechCrunch reported the company was founded in December 2025. (prnewswire.com) (techcrunch.com) In plain terms, the problem starts after software proposes promising drug candidates. Before a biologic drug can move forward, scientists still have to measure its exact molecular makeup, often with mass spectrometry, a technique that reads molecules by mass and charge. (techcrunch.com) (prnewswire.com) 10x Science said that step now takes weeks or months of manual analysis and reporting, using tools that “have not fundamentally changed in decades.” The company said its platform delivers automated molecular insights in minutes and can reason across hundreds of thousands of spectra, the signal traces produced by mass spectrometry instruments. (prnewswire.com) That pitch lands at a moment when drug developers can generate more candidates than their lab teams can fully evaluate. Y Combinator’s company page for 10x Science says artificial intelligence-powered discovery is flooding pipelines faster than scientists can characterize protein therapeutics for clinic-ready decisions. (ycombinator.com) The company’s founders say they built 10x Science after running into that bottleneck themselves in academia. The startup says David Roberts, Andrew Reiter, and Vishnu Tejus worked in Carolyn Bertozzi’s Stanford lab, where they studied molecular interactions involved in cancer and immunity. (prnewswire.com) (ycombinator.com) TechCrunch reported the software combines chemistry- and biology-based algorithms with artificial intelligence agents, and that the team trained models on spectrometry data while trying to keep the output traceable for regulatory use. That traceability matters because biologic drugs must be shown to be safe, effective, and manufacturable before they advance. (techcrunch.com) (prnewswire.com) 10x Science is still small by headcount. Y Combinator’s directory lists the company as a Winter 2026 batch startup with three employees in San Francisco and says it already has enterprise pharmaceutical customers. (ycombinator.com) The company is selling speed, but also labor savings. In its Y Combinator launch post, 10x Science said its software can cut analysis time from weeks to minutes and save more than $150,000 per team per month by reducing manual data work. (ycombinator.com) The next test is whether those claims hold up inside large drug-development workflows, where faster analysis only matters if scientists and regulators trust the result. For now, investors are betting that the slowest part of protein-drug development is still slow enough to fund. (techcrunch.com) (prnewswire.com)